CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced that its Chief Executive Officer Nancy Simonian, M.D., will present a corporate overview at the 35th Annual J.P. Morgan Healthcare Conference. Details are as follows:
35th Annual J.P. Morgan Healthcare Conference
Date: Wednesday, January 11
Time: 3 p.m. PT (6 p.m. ET)
Location: Westin St. Francis Hotel, 335 Powell Street., San Francisco, CA
The presentation will be followed by a question and answer session.
A live webcast of the presentation and question and answer session can be accessed under Events & Presentations in the News and Investors section of the Company's website at www.syros.com. A downloadable copy of the corporate slide presentation is also available on the News and Investors section of the website. A replay of the webcast will be archived on the website for approximately 30 days following the presentation.
About Syros Pharmaceuticals
Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and immune-mediated diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor with potential in a range of solid tumors and blood cancers. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.